Drug Development Pharma - July 16, 2015
Priority Review for Janssen Drug
The US Food and Drug Administration (FDA) has approved under priority review Janssen Pharmaceuticals’ New Drug Application (NDA) for the three-month long-acting atypical antipsychotic Invega Trinza. Priority review is a designation for drugs that, if approved, would offer significant improvement in the treatment of serious conditions. In a long-term maintenance trial, 93 percent of patients […]
Drug Development Pharma - June 9, 2015
Janssen Submits BLA to FDA
Genmab A/S’s licensing partner Janssen Biotech, Inc. has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for daratumumab for double refractory multiple myeloma. The submission is for using daratumumab to treat patients with multiple myeloma who have received at least three different lines of therapy […]
Acquisition - April 7, 2015
Depomed Buys US Rights to Janssen Franchise
Depomed, Inc. has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), an immediate release version of tapentadol, for management of moderate to severe […]
Funding - March 25, 2015
Janssen Joins Dementia Project
Johnson & Johnson’s Janssen Pharmaceutical Companies plan to invest $10 million in a new UK government-led global dementia discovery fund for research to find ways to prevent and treat dementia and Alzheimer’s disease. The investment will come through its affiliate venture arm, Johnson & Johnson Innovation – JJDC, Inc. The global Dementia Discovery Fund brings […]
Collaboration - December 15, 2014
Genmab Earns Milestone Fee
Genmab A/S announced it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc., triggering a $3 million payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. “This milestone marks further progress in our DuoBody collaboration with Janssen. There are now 10 bispecific antibody programs […]
Pharma Business - December 2, 2014
Study: Biopharm Has High Risks, Uncertainty
A first-of-its kind comparison of the business risks confronting six key European industries revealed that the biopharmaceutical sector faces the highest level of risk and economic uncertainty. The study conducted by Deloitte and commissioned by Janssen, compared six industry sectors: the biopharmaceutical industry, commercial aircraft manufacturing, the automotive industry, consumer electronics, food manufacturing and generic […]
